AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27593436 — intervention group
Group type: EXPERIMENTAL
Intervention: SAQ training (12-week intervention, 2 days/week)
Number of subjects: 35
Study 25060545 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% FiO2
Number of subjects: 81
Study 25060545 — intervention group
Group type: COMPARATOR
Intervention: 30% FiO2
Number of subjects: 81
Study 15662516 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal dilatation
Number of subjects: 60
Study 15662516 — intervention group
Group type: COMPARATOR
Intervention: No anal dilatation (control)
Number of subjects: 60
Study 15662516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 12131107 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI guidance
Number of subjects: 306
Study 12131107 — intervention group
Group type: COMPARATOR
Intervention: Standard practice control
Number of subjects: 306
Study 12131107 — intervention group
Group type: COMPARATOR
Intervention: Historic control
Number of subjects: 306
Study 9925702 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic evaluation
Number of subjects: 60
Study 9925702 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) evaluation
Number of subjects: 60
Study 9925702 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS evaluation
Number of subjects: 60
Study 9925702 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 60
Study 7503183 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined replacement therapy (group B): 2 mg of estradiol, 1 mg of estriol, and 1 mg of norethisterone acetate daily for 12 days per month.
Number of subjects: 140
Study 7503183 — intervention group
Group type: COMPARATOR
Intervention: Sequential estrogen-progestogen replacement therapy (group A): 2 mg of estradiol valerate daily and 5 mg of medroxyprogesterone acetate daily for 12 days per month.
Number of subjects: 140
Study 7503183 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 140
Study 2196946 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy (trained for 8 weeks, one hour a week, continued exercising twice daily for one year)
Number of subjects: 35
Study 2196946 — intervention group
Group type: COMPARATOR
Intervention: Non-specific counselling (same attendance schedule, no training, just sit and relax twice a day)
Number of subjects: 35
Study 7381637 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital 5 mg/kg in a single daily dose
Number of subjects: 79
Study 7381637 — intervention group
Group type: COMPARATOR
Intervention: Placebo with riboflavin tracer
Number of subjects: 79
Study 30477009 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet-based induction therapy with Carfilzomib, Lenalidomide, and Dexamethasone followed by Lenalidomide maintenance therapy
Number of subjects: 0
Study 28292764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigs for Peace (PFP)
Number of subjects: 0
Study 28292764 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbits for Resilience (RFR)
Number of subjects: 0
Study 28292764 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group
Number of subjects: 0
Study 25427877 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual cessation support plus a retail voucher to the value of NZ$25 for each 'abstinent from smoking' week for 8 weeks (voucher)
Number of subjects: 24
Study 25427877 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual cessation support plus product to the value of NZ$25 for each 'abstinent from smoking' week for 8 weeks (product)
Number of subjects: 24
Study 25427877 — intervention group
Group type: COMPARATOR
Intervention: Usual cessation support (control)
Number of subjects: 24
Study 23295472 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency transcutaneous electrical nerve stimulation (LF-TENS) for 30 minutes daily for 10 days
Number of subjects: 33
Study 23295472 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS for 30 minutes daily for 10 days
Number of subjects: 33
Study 21592295 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 4 mg twice daily
Number of subjects: 209
Study 21592295 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg once daily
Number of subjects: 209
Study 21592295 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin
Number of subjects: 209
Study 21592295 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 209
Study 18089891 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG oil
Number of subjects: 25
Study 18089891 — intervention group
Group type: COMPARATOR
Intervention: TAG oil
Number of subjects: 25
Study 16479517 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV-4
Number of subjects: 160
Study 16479517 — intervention group
Group type: EXPERIMENTAL
Intervention: MPSV-4
Number of subjects: 160
Study 12926339 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surgical policy based on prognosis of bleeding recurrence probability
Number of subjects: 818
Study 12926339 — intervention group
Group type: COMPARATOR
Intervention: Systemic hemostatic therapy, antisecretory drugs, methods of endoscopic hemostasis
Number of subjects: 818
Study 12926339 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamical determination of pO2 in periulcerous zone
Number of subjects: 818
Study 12926339 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of gastroduodenal ulcer bleeding
Number of subjects: 818
Study 10856108 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 414
Study 10856108 — intervention group
Group type: COMPARATOR
Intervention: Conventional amphotericin B
Number of subjects: 414
Study 9378690 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75-225 mg) once daily
Number of subjects: 191
Study 9378690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 8269047 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed appointment method
Number of subjects: 800
Study 8269047 — intervention group
Group type: COMPARATOR
Intervention: Open letters of invitation
Number of subjects: 800
Study 3081868 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding (initiated on day 1 of life)
Number of subjects: 34
Study 3081868 — intervention group
Group type: COMPARATOR
Intervention: Late enteral feeding (initiated on day 7 of life)
Number of subjects: 34
Study 3081868 — intervention group
Group type: COMPARATOR
Intervention: Minimally sick, very low birth weight neonates (control group)
Number of subjects: 34
Study 27932625 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (GECS)
Number of subjects: 64
Study 27932625 — intervention group
Group type: COMPARATOR
Intervention: Inverse graduated elastic compression stockings (PECS)
Number of subjects: 64
Study 29949328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongkuaixiao ointment (TKXO)
Number of subjects: 130
Study 29949328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 24752284 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Training
Number of subjects: 50
Study 24752284 — intervention group
Group type: COMPARATOR
Intervention: Delayed Training
Number of subjects: 50
Study 21992858 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D (1000 IU for <1 year and 2000 IU for >1 year) once a day for 5 days
Number of subjects: 200
Study 21992858 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose) once a day for 5 days
Number of subjects: 200
Study 21992858 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D (1000-2000 IU per day for 5 days)
Number of subjects: 200
Study 21992858 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 200
Study 20345740 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 hours of accelerated artificial daylight aging
Number of subjects: 40
Study 20345740 — intervention group
Group type: COMPARATOR
Intervention: 0 hours of accelerated artificial daylight aging
Number of subjects: 40
Study 20345740 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 hours of accelerated artificial daylight aging
Number of subjects: 40
Study 20345740 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 hours of accelerated artificial daylight aging
Number of subjects: 40
Study 20345740 — intervention group
Group type: COMPARATOR
Intervention: 0 hours, 400 hours, and 600 hours of aging
Number of subjects: 40
Study 18285358 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI group (patients with a history of PCI)
Number of subjects: 2489
Study 18285358 — intervention group
Group type: COMPARATOR
Intervention: Non-PCI group (patients without a history of PCI)
Number of subjects: 2489
Study 15811151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmented instructional video (8 short clips)
Number of subjects: 28
Study 15811151 — intervention group
Group type: COMPARATOR
Intervention: Complete sequential video
Number of subjects: 28
Study 12723743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine (10, 5, and 5 mg/kg) at 24-hour intervals
Number of subjects: 144
Study 12723743 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (0.2 mg/kg at 12-hour intervals)
Number of subjects: 144
Study 12723743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine
Number of subjects: 144
Study 12723743 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 144
Study 12723743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (prophylaxis)
Number of subjects: 144
Study 12723743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 144
Study 10229431 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nonsteroidal antiinflammatory drugs (n=352)
Number of subjects: 423
Study 10229431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=121)
Number of subjects: 423
Study 8522712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (525 mg/24 h)
Number of subjects: 273
Study 8522712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (1,050 mg/24 h)
Number of subjects: 273
Study 8522712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (2,100 mg/24 h)
Number of subjects: 273
Study 1662325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophane membrane
Number of subjects: 18
Study 1662325 — intervention group
Group type: EXPERIMENTAL
Intervention: AN 69 membrane
Number of subjects: 18
Study 1662325 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 18
Study 6811710 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 0
Study 6811710 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum food intake
Number of subjects: 0
Study 6811710 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel at rest and TPN
Number of subjects: 0
Study 31444872 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented implementation facilitation
Number of subjects: 197
Study 31444872 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging support
Number of subjects: 197
Study 31444872 — intervention group
Group type: COMPARATOR
Intervention: Usual implementation
Number of subjects: 197
Study 27828927 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ketamine administered intravenously during ECT under propofol anesthesia
Number of subjects: 132
Study 27828927 — intervention group
Group type: COMPARATOR
Intervention: Isovolumetric placebo (normal saline) administered during ECT under propofol anesthesia
Number of subjects: 132
Study 24923232 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein breakfast (egg)
Number of subjects: 156
Study 24923232 — intervention group
Group type: COMPARATOR
Intervention: Control breakfast (steamed bread)
Number of subjects: 156
Study 25171148 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 212
Study 25171148 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 212
Study 22974554 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz HF‐rTMS
Number of subjects: 16
Study 22974554 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 19201391 — intervention group
Group type: COMPARATOR
Intervention: Silicone IOL (CeeOn 911A; AMO)
Number of subjects: 44
Study 19201391 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL (AcrySof MA60BM; Alcon)
Number of subjects: 44
Study 18001250 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac ophthalmic solution 0.09%
Number of subjects: 527
Study 18001250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study 15056183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 12
Study 15056183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 12
Study 15056183 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 11799287 — intervention group
Group type: EXPERIMENTAL
Intervention: ChemFlex (Dentsply DeTrey)
Number of subjects: 89
Study 11799287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX GP (GC)
Number of subjects: 89
Study 9728672 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs (fluvoxamine, fluoxetine, paroxetine, sertraline) at recommended daily dosages for 6 weeks
Number of subjects: 0
Study 9728672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7645712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy by facemask
Number of subjects: 12
Study 7645712 — intervention group
Group type: COMPARATOR
Intervention: Blinded air by facemask
Number of subjects: 12
Study 2520418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (5 mg/kg body weight)
Number of subjects: 10
Study 2520418 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo)
Number of subjects: 10
Study 2520418 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine and placebo
Number of subjects: 10
Study 1092276 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly sulphadoxine-pyrimethamine
Number of subjects: 1000
Study 1092276 — intervention group
Group type: COMPARATOR
Intervention: Weekly chloroquine
Number of subjects: 1000
Study 1092276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 30120600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (2 x 50 mg)
Number of subjects: 30
Study 30120600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30120600 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan and Placebo
Number of subjects: 30
Study 30120600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 30
Study 27352250 — intervention group
Group type: EXPERIMENTAL
Intervention: Social app
Number of subjects: 95
Study 27352250 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect app
Number of subjects: 95
Study 24578607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections of local anesthetic (lidocaine 0.5%, 5 mL)
Number of subjects: 120
Study 24578607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections of local anesthetic (0.5% lidocaine, 4 mL) mixed with 1 mL or 6 mg of nonparticulate betamethasone
Number of subjects: 120
Study 21885867 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic treadmill exercise (TAEX)
Number of subjects: 38
Study 21885867 — intervention group
Group type: COMPARATOR
Intervention: Conventional care physiotherapy (Control)
Number of subjects: 38
Study 20660280 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A (HD-VA) supplement (209.8 micromol; 60 mg)
Number of subjects: 8
Study 20660280 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable isotope (SI)-labeled vitamin A (17.5 micromol; 5 mg)
Number of subjects: 8
Study 18355327 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus 1 OAD
Number of subjects: 865
Study 18355327 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus >1 OAD
Number of subjects: 865
Study 18355327 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (both groups)
Number of subjects: 865
Study 16331544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography (CBCT)
Number of subjects: 417
Study 16331544 — intervention group
Group type: COMPARATOR
Intervention: Dental computed tomography (Dental CT)
Number of subjects: 417
Study 11331428 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (30 mg)
Number of subjects: 15
Study 9438978 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 capsules of green tea extract (225 mg EGCg, 7.5 mg EGC)
Number of subjects: 3
Study 9438978 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 capsules of green tea extract (375 mg EGCg, 12.5 mg EGC)
Number of subjects: 3
Study 9438978 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 capsules of green tea extract (525 mg EGCg, 17.5 mg EGC)
Number of subjects: 3
Study 8175973 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (P)
Number of subjects: 18
Study 8175973 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (S)
Number of subjects: 18
Study 3068971 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month exercise programme
Number of subjects: 0
Study 3068971 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study 2773967 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgotein (8 mg to 32 mg) administered as an intra-articular injection once a week for three weeks
Number of subjects: 139
Study 2773967 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered as an intra-articular injection once a week for three weeks
Number of subjects: 139
Study 31408137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP goal < 120 mm Hg, n=355)
Number of subjects: 670
Study 31408137 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (SBP goal < 140 mm Hg, n=315)
Number of subjects: 670
Study 31408137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP goal < 120 mm Hg)
Number of subjects: 670
Study 31408137 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (SBP goal < 140 mm Hg)
Number of subjects: 670
Study 28549480 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing (AD) intervention
Number of subjects: 40
Study 28549480 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 40
Study 26355618 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreens plus DNA repair enzymes (enzyme group)
Number of subjects: 28
Study 26355618 — intervention group
Group type: COMPARATOR
Intervention: Sunscreens alone (sunscreen group)
Number of subjects: 28
Study 24367678 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine-based antiretroviral therapy
Number of subjects: 573
Study 24367678 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-based antiretroviral therapy
Number of subjects: 573
Study 21310350 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical resection at 90° angle with MTA obturation (Group 1)
Number of subjects: 46
Study 21310350 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical resection at 90° angle with ultrasonic preparation and MTA obturation (Group 2)
Number of subjects: 46
Study 21310350 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical resection at ∼45° angle with MTA obturation (Group 3)
Number of subjects: 46
Study 21310350 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical resection at ∼45° angle with ultrasonic preparation and MTA obturation (Group 4)
Number of subjects: 46
Study 21310350 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 46
Study 21310350 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 46
Study 20030843 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB-based behavioral intervention (12-week duration, starting 2 weeks post-implantation)
Number of subjects: 350
Study 20030843 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 350
Study 20030843 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB-based behavioral intervention
Number of subjects: 350
Study 17113831 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological intervention (low in total and saturated fat, trans fats, higher in fiber, promotes loss of 7-10% of body weight, includes at least 150 min of physical activity per week)
Number of subjects: 508
Study 17113831 — intervention group
Group type: COMPARATOR
Intervention: Health education (control group)
Number of subjects: 508
Study 15163773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2950
Study 15163773 — intervention group
Group type: COMPARATOR
Intervention: PSA level 0.5 ng/mL or less
Number of subjects: 2950
Study 15163773 — intervention group
Group type: COMPARATOR
Intervention: PSA level 0.6 to 1.0 ng/mL
Number of subjects: 2950
Study 15163773 — intervention group
Group type: COMPARATOR
Intervention: PSA level 1.1 to 2.0 ng/mL
Number of subjects: 2950
Study 15163773 — intervention group
Group type: COMPARATOR
Intervention: PSA level 2.1 to 3.0 ng/mL
Number of subjects: 2950
Study 15163773 — intervention group
Group type: COMPARATOR
Intervention: PSA level 3.1 to 4.0 ng/mL
Number of subjects: 2950
Study 11210401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (2.4 g doses)
Number of subjects: 0
Study 11210401 — intervention group
Group type: COMPARATOR
Intervention: Control (without sevelamer)
Number of subjects: 0
Study 9596048 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (n = 24)
Number of subjects: 101
Study 9596048 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy with imipramine (n = 26)
Number of subjects: 101
Study 9596048 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy (n = 24)
Number of subjects: 101
Study 9596048 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (n = 27)
Number of subjects: 101
Study 8311598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow during cardiopulmonary bypass
Number of subjects: 10
Study 8311598 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile flow during cardiopulmonary bypass
Number of subjects: 10